NCT00774020View on ClinicalTrials.gov

Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 30, 2008

Primary Completion Date

January 14, 2011

Study Completion Date

January 14, 2011

Conditions
Paget's Disease of Bone
Interventions
DRUG

Zoledronic acid

5mg, i.v. single dose

Trial Locations (4)

Unknown

Novartis Investigative Site, Beijing

Novartis Investigative site, Guangzhou

Novartis Investigative site, Nanjing

Novartis Investigative site, Shanghai

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY